Kallikrein-12 Antibodies

Kallikrein-12 (KLK12)

Gene Information

Human
Gene Name:	KLK12
Uniprot:	Q9UKR0
Entrez:	43849

Family

Belongs to:
peptidase S1 family

Alternative Names

DKFZp686H1078; EC 3.4.21; EC 3.4.21.-; Kallikrein 12; Kallikrein-like protein 5; kallikrein-related peptidase 12; KLK12; KLK-L5; KLKL5kallikrein-12; KLK-L5MGC42603

Molecular Weight

Mass (kDA):
26.734 kDA

Genomic Context

Human
Location:	19q13.41
Sequence:	19; NC_000019.10 (51028954..51035648, complement)

Subcellular Localizations

Secreted.

Diseases

• Malignant Neoplasms
• Neoplasms
• Malignant Neoplasm Of Breast
• Carcinogenesis
• Carcinoma
• Mammary Neoplasms
• Malignant Neoplasm Of Prostate
• Adenocarcinoma
• Lung Neoplasms
• Malignant Neoplasm Of Stomach
• Stomach Neoplasms
• Neoplasm Metastasis

• Overlying Behavior
• Metastatic Malignant Neoplasm To The Lymph Node
• Dermatitis, Atopic
• Infertility
• Malignant Neoplasm Of Lung
• Tumor Angiogenesis
• Carcinoma, Large Cell

Pathways

• Pathogenesis
• Localization
• Reverse Transcription
• Cell Proliferation
• Cell Migration
• Zymogen Activation
• Proteolysis

• Angiogenesis

PTMs

• Cleavage

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/KLK12

Best Uses of the KLK12 Marker

You may be wondering about how to use KLK12 markers for research purposes. This article will explain the KLK12 gene expression, how to combine with other markers and clinical applications. Boster Bio can be reached for any questions. We will respond quickly and efficiently to your questions. We appreciate your time! We look forward to hearing back from you! Continue reading for more information. These are some of my favorite uses of KLK12 markers.

Expression of a KLK12 marker

The regulation of cell proliferation, and apoptosis has been shown by the expression of the KLK12 marker in boster cell lines. This protein has not yet been studied in macrophages infected in mycobacteria. The gene has been implicated with a variety of human diseases, including ovarian cancer, rheumatoid and apoptosis.

The kallikrein-related peptidases (KLK), a family of secreted serin proteases, plays a variety of roles in the body. This protein family plays an important role for ECM remodeling. In addition to these important roles, kallikrein-related peptidases have shown promising potential as biomarkers for cancer.

Recently, bovine macrophages with M. bovis infection showed KLK12 expression. This may be an important role in the diagnosis and treatment of bovine TB. Furthermore, KLK12 is closely associated with apoptosis and autophagy. It also affects the expression of cytokine in these cells. This is an important step for determining whether or otherwise a KLK12 proteins is essential for the immune reaction.

Transient transfection of BMDM cells with siRNA for the expression of a KLK12 gene in Boster Bio. The cells were incubated for the indicated time period and were lysed using 0.1% Triton X100. The transfected cells were then incubated for 48 hours in digitonin buffer. Following this, OD values were determined at 490 nm using an ELISA plate reader.

KLK12 is only one member of the KLKs genes family. The KLKs gene families has 15 other members. This results in a variety of proteins that are important in the immune system. The genes encoding the gene can be found in many tissues including fetal and adult skin. KLKs are closely related to human adaptation against influenza virus A. The gene is mapped to chromosome 7 near Tam-1 locus.

This gene encodes an enzyme called serine protease which works on kallikrein. It is found in the cell's cytoplasm. Steroid hormones activate it. Many companies offer customized genome-editable KLK12 models that can be used to test the gene in patients. Cas9 nuclease and Cas9 proteins are also available. They are also able to control lentiviruses containing GFP and RFP as well as Luciferase.

Combinations with other marker

A large SE and/orSP value is the optimal number of markers to include in a panel. A low SE/SP is considered negligible clinically. Figure 2A shows the distributions of these metrics as a function o the frequency positive combinations. These combinations are then selected to be the "golden markers". Tabular data is provided for each combination. It includes the relative SE/SP values and the composition of individual markers in the panel.

The CombiROC web application is a statistically rigorous and user-friendly tool for determining the optimal marker combinations. It allows users the ability to compare multiple samples with double-filter scores. This will allow them to determine each marker's sensitivity or specificity. Once the process is complete, the user will be able to view and manipulate the ROC curves of the selected combination. A graphical user interface helps with the final decision. The CombiROC application uses Shiny as an application framework.

The second phase in ROC analysis involves calculating sensitivity (SE), as well as specificity (SP), for combinations with different marker combinations. The ROC curves then evaluate the selected combination to determine the best performing. This is repeated for each candidate combination until all combinations have been deemed optimal. Sometimes, multiple combinations may need to be tested using ROC analysis of markers. The goal is for combinations to be identified with the greatest specificity possible and accuracy.

In a study comparing diagnostic performance of single biomarkers AFP, NLR, ALT were found to be similar. Combinations with these biomarkers led to the highest AUC of 0.773 and the highest sum-of-sensitivity and specificity of 1.524, compared to all other combinations. In the absence of reliable data, it's prudent to consider other markers.

Combinations with microRNAs gave excellent results. Using CombiROC, a subset of 5 microRNAs from 50 samples was used to measure AUCs of combinations and single markers. The resulting distribution shows that combinations containing one microRNA have a higher accuracy than single markers. There are two types of CombiROC, one for single microRNAs and one for combinations. Combining single markers with combinations of microRNAs will have a higher AUC.

Clinical applications

Eight members of the human kallikrein gene familia have a common molecular profile. The members of the family are found in almost all human tissues. They catalyze many physiological processes. These proteins can be used as both single enzymes or as part of complex proteolytic cascades. This family has attracted a lot of attention in recent years. However, a number of questions remain regarding the role of KLKs in disease and the potential for clinical applications.

The KLK12 genes' role in tumor invasion, metastasis, and metastasis was the first clinical application. These processes are essential for tumor progression. They are also known to be the primary causes after radical surgery. There are several steps involved in tumor metastasis, including invasion through basement membrane. In the present study, cells from KLK12-suppressed and MKN-45-suppressed mice migrated significantly slower across polycarbonate membranes, while their parent cells migrated less efficiently. KLK12-suppressed mice cells showed no difference in invasion rates between parent and KLK12suppressed cells. In addition, other KLKs are known to degrade the extracellular matrix.

Furthermore, this gene has been implicated in colorectal cancer. The mechanisms that underlie colorectal cancer's effects are not yet understood. The present study, which examined KLK12 and colorectal disease, gave new insight into the mechanisms of this gene. In this regard, the KLK12 gene is a promising new marker for detecting cancer. It has many clinical applications, including screening for a wide array of cancer types.

A plasmid containing KLK12 was used to transfect HT-29 cells. The cells were then allowed to remain transfected for 90 minutes and then for 12-24 hours. A melting curve analysis was then performed to determine KLK12 mRNA expression. Relative quantification was done using a two-Ct technique. These experiments resulted in the creation of a standard curve of KLK12.

Knockdown KLK12 in HT29 cells resulted increased cell death. The anti-apoptosis protein Bcl2 was significantly downregulated in cells treated with the siKLK12 plasmid. This demonstrates that KLK12 is an essential protein in suppressing apoptosis. However, it is still necessary to investigate the exact mechanism of KLK12.

Researchers used small interferingRNAs (siRNAs) to decrease the expression of KLK12 to further investigate its clinical applications. Lipofectamine(r), 2000 was used as a transfection reagent to transfect siRNA in HT-29 cells. RTPCR and Western blot analysis proved that transfection succeeded. KLK12 expression significantly increased cell viability in HT-29 cells when transfected.

The KLK12 genes has been found to overexpress in colorectal tumour tissues. Although its functions are still not fully understood, recent research has shown that the gene regulates AMPK/mTOR pathway signaling pathways. It may therefore be a useful marker for patients with colorectal carcinoma. It is currently used to assess tumor growth. But it has a long journey ahead.